ab-1005
Gene therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2026 (NCT07215403)
Timeline
2020s
- Jan 1, 2026
Earliest Phase 2 Sponsor(trial)
Mechanism of action
- Glial cell line-derived neurotrophic factorSupplementation
GDNF supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07215403 | Phase 2 | May 1, 2026 | Asklepios BIoPharmaceutical, Bayer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Asklepios BIoPharmaceutical | For profit | 1 | 1 | 1 | 2026 |
| Bayer | For profit | 1 | 0 | 1 | 2026 |
2 organizations
Page 1 / 1